Homepage
Author:
SpyGlass Pharma, Inc.
Posted Date:
March 9, 2026
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
SpyGlass Pharma, Inc.
March 9, 2026
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
SpyGlass Pharma, Inc.
March 4, 2026
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
SpyGlass Pharma, Inc.
February 11, 2026
SpyGlass Pharma Announces Pricing of Initial Public Offering
SpyGlass Pharma, Inc.
February 11, 2026
